Mike Havrilla
View Mike Havrilla's Articles BY TICKER:
ABT,
ACCP.OB,
ACEL.PK,
ACOR,
ACRX,
ADLS.PK,
AEZS,
ALTH,
ALXA,
ALZYF.PK,
AMAG,
AMGN,
AMRN,
ANAC,
ANIK,
ANSV,
APPY,
BDSI,
BLRX,
BNVI.PK,
BPA,
BPAX,
BWTR,
CBMX,
CEMI,
CLDX,
CLRT,
CLSN,
CORX.OB,
CPD,
CPIX,
CRTX,
CRVW.OB,
CSIQ,
CTIC,
CXCHF.PK,
CXG,
CYTX,
DCTH,
DRTX,
DSCO,
ECTE,
EICU,
EXAS,
FAA,
FCF,
FLML,
FOLD,
IMUC,
INO,
INSV.OB,
IPCI,
IRWD,
JAV,
KERX,
KG,
KOOL,
LCI,
LDIS,
MELA,
MNTA,
MNTR.PK,
MSTX,
NBS,
NEPH.OB,
NEPT,
NFEC,
NGSX.OB,
NIVS.PK,
NSSC,
NTEC,
NYMX,
OSUR,
PATH,
PBI,
PCRX,
PFE,
PLX,
PTIE,
PTXRF.PK,
RAD,
RIGL,
RMTI,
ROCM,
RSX,
SNSS,
SNUS,
SNY,
SUPN,
TESS,
TGEN,
TPTX,
TTNP.OB,
UDRY.OB,
UNIS,
VNDA,
VVUS,
WB,
YMI
- Venaxis Poised For Run-Up Into Pivotal Study Results
- Titan Pharma: Trading The FDA Run-Up, Round 2
- Nymox Pharma: Developing A Potential Long-Term Treatment For BPH
- Rockwell Poised For Post-Offering Bounce Ahead Of Phase III Results
- Flamel: Near-Term, Under The Radar FDA Catalyst Trade
- Delcath Poised For Run-Up Into FDA Advisory Panel Meeting
- Durata Therapeutics: Low Floater With Near-Term Phase III Catalyst
- AcelRx Pharma: Pain Drug Developer With A Pair Of Q1 2013 Phase III Catalysts
- Chembio Diagnostics: Growing Sales And Profits With Near-Term FDA Catalyst
- BioLineRx: Israeli Biotech Incubator With Multiple Near-Term Clinical Catalysts
- Anika Therapeutics: Growth Stock At Value Prices With Near-Term FDA Catalyst
- Anacor Pharma Poised For Rebound Ahead Of Phase III Results
- Amicus Therapeutics Poised For Rebound Into December Phase III Results
- Lannett Returns To Profitability, Reports Strong Sales Growth
- Alexza Poised For Run-Up Into December U.S., EU Approval Decisions
-
Unilife Poised For Short- And Long-Term Gains
- Rigel Pharma: Key RA Drug Data Expected Late 2012 Through H1 2013
- Intellipharmaceutics: Drug Delivery Specialist With Potential FDA Approval And Partnership Catalysts
- A Near-Term FDA Catalyst For Cornerstone Therapeutics With Hospital-Focused Strategy
- Ironwood Pharma: FDA Decision Expected Within Weeks For GI Drug
- Sunesis Poised For Run-Up Into Phase III Interim Analysis Next Month
-
Amicus Therapeutics: Rare Disease Drug Developer Expected To Reveal Phase III Results In 3Q12
- AcelRx Pharma: Pain Drug Developer With 2H12 Phase 3 Catalysts
- AMAG Receives EU Approval For Iron Drug With Phase III Results Expected Soon
- Lannett: Small-Cap Growth Pharma Trading At Value Prices
- BioLineRx: An Israeli Biotech Incubator
- Neptune Reports Strong Sales Growth Ahead Of Phase II Results
- Vanda Pharma: Trading Below Cash With Upcoming Catalysts Expected 2H12
- 5 Near-Term, Low-Priced Bio-Catalyst Trades
- EXACT Sciences: Pivotal Colon Cancer Screening Test Results Expected Later This Year
- Endo Pharma Deal Validates BioDelivery Sciences Pipeline Potential
- Supernus Pharma: A Recent IPO Awaiting Pair Of FDA Decisions